What patent is “fidaxomicin” in the EU tied to?
The key “fidaxomicin” patent questions in the EU usually center on the original product protection (often via composition-of-matter and related exclusivity) for Dificid (fidaxomicin), plus any follow-on patents on specific formulations, dosing regimens, or manufacturing. The exact patent(s) depend on the product and the country within the EU/EEA, and whether you’re looking for the original marketing authorisation versus later licensed indications.
When does fidaxomicin’s patent/exclusivity expire in Europe?
There isn’t enough information in your message to name the specific EU patent number, holder, or the exact country (e.g., UK, Germany, France, or EU-wide reference product protection). Those details determine the expiry date because:
- EU patent expiry is governed by the patent term for the particular patent family.
- EU drug exclusivity can extend beyond patent term through supplementary protection mechanisms (commonly discussed as “SPC” and related data/exclusivity protections).
- National enforcement and patent status can differ from a high-level “EU” statement.
Which countries should you check in the EU/EEA for fidaxomicin?
For EU and near-EU coverage, users typically check:
- The main countries where enforcement matters (e.g., Germany, France, Italy, Spain, Netherlands)
- EU/EEA members where launches or generic/biosimilar challenges are likely
- The UK if you’re comparing “EU vs UK” timelines, since the UK often has separate regulatory and legal paths
How do generics/“fidaxomicin generic in EU” typically play out if patents are still active?
If relevant fidaxomicin patents (or SPC/data exclusivity protections) are active, generic entry can be delayed. The practical effect is that:
- Generic or parallel-substitution plans may proceed only after patent/exclusivity expiry in the relevant jurisdiction.
- Companies sometimes challenge listed patents or argue non-infringement/invalidity to clear the way for earlier entry.
- Even when one patent family expires, other follow-on patents can still block launch.
What search terms or databases find the right EU fidaxomicin patent expiry dates?
To get the correct “fidaxomicin patent EU” expiry, you usually need to search by product and patent family using:
- The European Patent Register (EPO) for the patent family and member-state status
- National patent registers for enforcement and current validity by country
- Regulatory exclusivity/SPC registers tied to the marketed product (so you don’t rely only on patent publication dates)
What I need from you to give an exact expiry date
Send any one of the following and I can narrow it to the correct EU patent/exclusivity timeline:
- The exact product name (e.g., Dificid) and the EU country you care about
- The patent number or a link you found
- The patent holder/company name
- Whether you mean “EU patent expiry” (patents only) or “regulatory exclusivity/SPC expiry” (often what drives launch timing)
Quick clarification
When you say “Fidaxomicin patent eu,” do you want the expiry date for:
1) the underlying patent(s) (intellectual property), or
2) regulatory exclusivity/SPC periods in the EU (launch timing)?
Sources
No sources were provided with your question, so I can’t cite specific patent documents or expiry dates yet.